SAN DIEGO--(BUSINESS WIRE)--May. 29, 2012-- Illumina (NASDAQ:ILMN) today announced that the Queensland Centre for Medical Genomics(QCMG), home of Australia’s International Cancer Genomics Consortium program, has established Illumina technology as its core sequencing platform in an expanded facility. The QCMG will replace their fleet of SOLiD/5500 systems with three Illumina HiSeq 2500 systems. This new partnership began in April.
“Illumina is pleased to support the QCMG as a leader in Australian genome research. The decision of the QCMG to decommission their SOLiD/5500 systems and standardize on Illumina’s 2500 platform for high-throughput next generation sequencing is a strong endorsement of the superior capabilities of the HiSeq platform and will assist the QCMG to progress towards our shared vision of enabling the development of personalized medicine,” said
Tim Orpin, Vice President of Illumina’s Asia Pacific Region. “Illumina is proud of our long-term relationship with the QCMG. We are very excited to see a relationship that was founded on the use of Illumina genotyping arrays evolve to encompass next generation sequencing.”
Professor
Sean Grimmond, Director of the QCMG and lead for Australia’s ICGC efforts, added, “Adopting the HiSeq platform provides us with a much needed 3-4 fold increase in sequencing throughput. We also anticipate the HiSeq2500 upgrades will push this closer to 10 terabases a month in the near future. This change more closely aligns our ongoing efforts with the greater ICGC research community which predominantly uses Illumina platforms.”
“The increased sequencing capacity at the QCMG will allow the Australian team to look into new ICGC-related genome sequencing initiatives and also to establish an exome, whole genome and RNA sequencing service for The University of Queensland’s Institute for Molecular Bioscience (IMB). Scaling up our sequencing capacity at the IMB will allow us to better facilitate the success of in-house genome, transcriptome and bioinformatics projects.”
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
About QCMG
The Queensland Centre for Medical Genomics (QCMG) is located in The University of Queensland’s Institute for Molecular Bioscience. It was established in 2010 through support from the Queensland State Government and the University of Queensland. Its flagship project is the sequencing of 500 Pancreatic and cancer genomes as part the International Cancer Genome Consortium (ICGC).
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-429-8350
pr@illumina.com
